- Home
- HYFM vs AEON Comparison
HYFM vs AEON Comparison
Compare HYFM & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HYFM | AEON |
|---|---|---|
| Founded | 1977 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2M | 10.6M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | HYFM | AEON |
|---|---|---|
| Price | $1.98 | $1.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | 97.1K | ★ 157.1K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $146,443,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $37.86 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.50 | $0.38 |
| 52 Week High | $7.50 | $47.68 |
Technical Indicators
Market Signals| Indicator | HYFM | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 47.39 | 62.98 |
| Support Level | $1.51 | $0.72 |
| Resistance Level | $2.74 | $1.10 |
| Average True Range (ATR) | 0.31 | 0.10 |
| MACD | 0.06 | 0.04 |
| Stochastic Oscillator | 32.11 | 81.26 |
Price Performance
Historical ComparisonAbout HYFM Hydrofarm Holdings Group Inc.
Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.